MedTrace Logo

ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas

NCT05079022 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2021-10-15

No results posted yet for this study

Summary

The purpose of this study is to determine the feasibility and effectiveness of ctDNA-MRD based adjuvant furmonertinib therapy in EGFR mutation-positive stage I lung adenocarcinoma patients after complete surgical resection.

Conditions

  • Adenocarcinoma of Lung

Interventions

DRUG

Furmonertinib

Furmonertinib at 80mg dose will be administered orally once daily.

Sponsors & Collaborators

  • Beijing CSCO-Allist Cancer Research Foundation

    collaborator UNKNOWN

  • Shanghai Allist Pharmaceutical Technology Co., Ltd.

    collaborator UNKNOWN

  • Guangzhou Burning Rock Medical Examination Institute Co., Ltd.

    collaborator INDUSTRY

  • Peking University People's Hospital

    lead OTHER

Principal Investigators

  • Fan Yang, MD · Peking University People's Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-31
Primary Completion
2023-03-31
Completion
2024-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05079022 on ClinicalTrials.gov